San Diego, CA, United States
San Diego, CA, United States
SEARCH FILTERS
Time filter
Source Type

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to Discoidin Domain Receptor Family, Member 1 (DDR1). The invention provides a DDR1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the DDR1-binding agent to treat a DDR1-mediated disease.


The invention is directed to an in vitro method for introducing one or more insertion mutations and/or one or more deletion mutations in a nucleic acid sequence encoding a polypeptide. The method comprises contacting a cell in vitro with a nucleic acid sequence, and expressing Activation Induced Cytidine Deaminase (AID) in the cell. The invention also is directed to a method of producing an immunoglobulin.


Patent
AnaptysBio | Date: 2012-10-24

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.


Patent
AnaptysBio | Date: 2015-01-09

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.


Patent
AnaptysBio | Date: 2014-05-02

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease.


Patent
AnaptysBio | Date: 2013-09-19

The invention provides isolated amino acid sequences comprising the framework regions of an immunoglobulin heavy chain or light chain polypeptide, wherein certain amino acid residues of the framework regions are replaced with different amino acid residues that confer increased thermostability in vitro or in vivo. The invention also provides an isolated amino acid sequence of the constant region of an immunoglobulin heavy chain polypeptide wherein certain amino acid residues of the constant region are replaced with different amino acid residues that confer increased thermostability in vitro or in vivo.


Patent
AnaptysBio | Date: 2014-12-31

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.


Patent
AnaptysBio | Date: 2013-10-11

This invention relates to methods for the generation of humanized antibodies, particularly a humanized antibody heavy chain protein and a humanized antibody light chain protein. The method comprises using cells that express or can be induced to express Activation Induced Cytidine Deaminase (AID).


Patent
AnaptysBio | Date: 2014-02-14

This invention relates to methods for the generation of humanized antibodies, particularly a humanized antibody heavy chain protein and a humanized antibody light chain protein. The method comprises using cells that express or can be induced to express Activation Induced Cytidine Deaminase (AID).


The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to complement protein C5. The invention provides a C5-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention provides an isolated complement protein C5 epitope. The invention also provides related vectors, compositions, and methods of using the C5-binding agent to treat an C5-mediated disease.

Loading AnaptysBio collaborators
Loading AnaptysBio collaborators